Regulatory milestones

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) was off $0.09 to $54.87 last week after the company said the Japanese Ministry of Health, Labor and Welfare (MHLW) approved an NDA for Soliris eculizumab to treat paroxysmal nocturnal hemoglobinuria (PNH) under the ministry's Priority Review process (see Analyst Picks & Changes, A16).

Look for shares of BioAlliance Pharma S.A. (Euronext:BIO) to move on Monday this week on late Friday's news that FDA approved an NDA for Oravig miconazole to treat oropharyngeal candidasis in adults and children ages 16 and older. The approval triggers a $20 million milestone payment to BioAlliance from U.S. commercial partner Par Pharmaceutical Cos. Inc. (NYSE:PRX). BioAlliance was up €0.27 to €6 last week...